Non-Small Cell Lung Cancer: Sotorasib Treatment Study

We are studying the effects of Sotorasib in patients with non-operable non-small cell lung cancer who have a KRAS mutation. The goal is to see if this treatment improves survival and response rates compared to standard options.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Lumykras
Lumykras is a cancer medicine used to treat certain non-small cell lung cancers with a specific genetic change.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Sotorasib
Sotorasib targets a specific KRAS G12C mutation to help stop tumor growth in certain lung and other cancers.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Complexo Hospitalario Universitario A Coruna
Medical Oncology
A Coruña, Spain
Hospital General Universitario Dr. Balmis
Medical Oncology
Alicante, Spain
Hospital Universitari Dexeus Grupo Quironsalud
Medical Oncology
Amorebieta, Spain

Sponsor: Fundacion GECP
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.